Please enter exact key words
T-cell Redirecting Bispecific Antibody Targeting GPRC5D

for the Treatment of Multiple Myeloma

Home / Available Projects / T-cell Redirecting Bispecific Antibody Targeting GPRC5D
Drug Name GPCR-targeted Project 009

G-protein coupled receptor family C group 5 member D (GPRC5D) is overexpressed on certain tumors, such as multiple myeloma, while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation. A humanized T-cell redirecting bispecific antibody targeting both GPRC5D and CD3 antigen is being developed for the treatment of multiple myeloma. The antibody binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells to result in the cross-linking of T cells and tumor cells, thereby inducing a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells.

Target G protein-coupled receptor 5D (GPRC5D); CD3
Drug Modality Monoclonal antibody
Indication Multiple myeloma
Product Category Biologic
Mechanism of Action Antibody-dependent cell cytotoxicity
Status Preclinical
Patent Granted

More Detail Available Upon Request

We look forward to hearing from you.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry

Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.